More articles from News in Depth

Companies Scaling Back IDO1 Inhibitor Trials
Cancer Discovery Jul 2018, 8 (7) OF5; DOI: 10.1158/2159-8290.CD-ND2018-007
The Quest for Off-the-Shelf CAR T Cells
Cancer Discovery Jul 2018, 8 (7) 787-788; DOI: 10.1158/2159-8290.CD-ND2018-005
Warming “Cold” Melanoma with TLR9 Agonists
Cancer Discovery Jun 2018, 8 (6) 670; DOI: 10.1158/2159-8290.CD-ND2018-004
Q&A: Ned Sharpless on His Vision for NCI
Cancer Discovery Jun 2018, 8 (6) 669; DOI: 10.1158/2159-8290.CD-ND2018-006
STINGing Antitumor Immunity into Action
Cancer Discovery Mar 2018, 8 (3) 259-260; DOI: 10.1158/2159-8290.CD-ND2018-002
Venetoclax Data Prompt Rethink of CLL Therapy
Cancer Discovery Mar 2018, 8 (3) OF5; DOI: 10.1158/2159-8290.CD-ND2018-003
Gut Bacteria Shape Therapeutic Response
Cancer Discovery Feb 2018, 8 (2) 134; DOI: 10.1158/2159-8290.CD-ND2018-001
Checkpoint Inhibitors Spur Changes in Trial Design
Cancer Discovery Nov 2017, 7 (11) 1209-1210; DOI: 10.1158/2159-8290.CD-ND2017-006
Taking the Guesswork Out of Stopping TKIs
Cancer Discovery Sep 2017, 7 (9) 928; DOI: 10.1158/2159-8290.CD-ND2017-005
Why First-Line Nivolumab Is No Better than Chemo
Cancer Discovery Sep 2017, 7 (9) 927; DOI: 10.1158/2159-8290.CD-ND2017-004

Main menu